Safety, tolerability, and pharmacokinetics of TG-1000, a new molecular entity against influenza virus: first-in-human study

Background: The cap-snatching mechanism of influenza virus mRNA transcription is strongly suppressed by TG-1000, a prodrug rapidly metabolized into TG-0527, is a potent cap-dependent nucleic acid endonuclease inhibitor. Herein, we aimed to assess the safety, tolerability, and pharmacokinetics of TG-...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Su-Mei Xu, Li-Wen Chang, Cheng-Yuan Tsai, Wan-Li Liu, Dai Li, Shan-Shan Li, Xiao-Min Li, Ping-Sheng Xu
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2023-11-01
Serija:	Frontiers in Pharmacology
Teme:	first-in-human TG-1000 influenza safety tolerability pharmacokinetics
Online dostop:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1272466/full
Oznake:	Označite Brez oznak, prvi označite!